secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0000950170-23-006713
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics FY2022 net loss $123.7M; TN-201 IND cleared, Phase 1b Q3 2023
--------------------------------------------------------------------------------

- Net loss of $33.5M ($0.61/share) in Q4 2022 and $123.7M ($2.76/share) in FY2022.
- Cash and investments $204.2M at year-end; runway expected into first half 2025.
- TN-201 IND for MYBPC3 gene therapy cleared by FDA; Phase 1b dosing planned Q3 2023.
- TN-301 MAD stage dosing commenced; Phase 1 data from SAD/MAD expected H2 2023.
- TN-401 (PKP2 gene therapy) IND submission planned for H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/0000950170-23-006713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/tnya-20230308.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer